CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT04092270
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:29:08.150094+00:00
- Published At
- 2026-04-17T00:00:00+00:00
- Record Updated At
- 2026-04-17
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Endometrial High Grade Endometrioid Adenocarcinoma", "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube High Grade Serous Adenocarcinoma", "Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma", "FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Undifferentiated Carcinoma", "Platinum-Sensitive Ovarian Carcinoma", "Primary Peritoneal Carcinosarcoma", "Primary Peritoneal High Grade Serous Adenocarcinoma", "Primary Peritoneal Transitional Cell Carcinoma", "Primary Peritoneal Undifferentiated Carcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Ovarian Clear Cell Adenocarcinoma", "Recurrent Ovarian Endometrioid Adenocarcinoma", "Recurrent Ovarian Low Grade Serous Adenocarcinoma", "Recurrent Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor", "Recurrent Ovarian Mucinous Adenocarcinoma", "Recurrent Ovarian Transitional Cell Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-17"- protocolSection.identificationModule.nctId
"NCT04092270"- protocolSection.identificationModule.officialTitle
"A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.